SNDX - Syndax reports encouraging Phase 1 data for leukemia drug
2023-12-11 12:40:05 ET
More on Syndax Pharmaceuticals
- Syndax Pharmaceuticals Inc (SNDX) Q3 2023 Earnings Call Transcript
- Syndax: Biotech To Watch With Regulatory Filings Before End Of 2023
- BofA starts Syndax at buy, cites "first mover advantage" for leukemia drug
- Syndax initiated Buy at Goldman Sachs citing sales ops next year
- Seeking Alpha’s Quant Rating on Syndax Pharmaceuticals
For further details see:
Syndax reports encouraging Phase 1 data for leukemia drug